Lanean...
Early experience with remdesivir in SARS-CoV-2 pneumonia
At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients h...
Gorde:
| Argitaratua izan da: | Infection |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer Berlin Heidelberg
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7229436/ https://ncbi.nlm.nih.gov/pubmed/32418190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s15010-020-01448-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|